Welcome to our dedicated page for Xenon Pharmaceuticals SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xenon Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xenon Pharmaceuticals's regulatory disclosures and financial reporting.
Xenon Pharmaceuticals reported a larger net loss as it ramps late-stage development. For the quarter ended March 31, 2026, net loss widened to $102.3 million from $65.0 million a year earlier, driven by higher research and development and general and administrative costs and no milestone revenue.
R&D spending rose to $88.5 million, mainly for Phase 3 programs of azetukalner in epilepsy and depression and early-stage pain programs. Xenon strengthened its balance sheet with $843.0 million of financing cash inflows, including an underwritten equity and pre-funded warrant offering, ending the quarter with $1.34 billion in cash, cash equivalents and marketable securities to fund ongoing clinical trials and potential commercialization.
Xenon Pharmaceuticals reported a larger net loss in Q1 2026 as it ramps late‑stage neuroscience programs but highlighted pivotal clinical progress and a strengthened balance sheet. The company posted a net loss of $102.3 million (vs. $65.0 million a year ago), driven by higher research and development and general and administrative expenses and the absence of prior collaboration revenue.
Cash, cash equivalents, and marketable securities rose to $1.34 billion as of March 31, 2026, after raising $130.0 million via an at‑the‑market program and $707.6 million through a public offering, extending cash runway into 2029. Xenon reported positive Phase 3 X‑TOLE2 data for azetukalner in focal onset seizures, with a placebo‑adjusted median percent change in monthly seizure frequency of -42.7% at 25 mg, and plans a New Drug Application submission in Q3 2026. Multiple additional Phase 3 studies in epilepsy and mood disorders, as well as Phase 1 pain programs targeting NaV1.7 and KV7, continue to enroll or progress.
Xenon Pharmaceuticals Inc. is asking shareholders to vote at a virtual-only annual meeting on June 2, 2026. Holders of common shares as of April 7, 2026 can attend via webcast and have one vote per share on each proposal.
Shareholders will be asked to elect eight directors, approve on an advisory basis executive compensation and the frequency of future say‑on‑pay votes, approve a new 2026 Equity Incentive Plan, appoint PricewaterhouseCoopers LLP as auditor, and authorize the Audit Committee to set auditor remuneration. Directors are elected under a majority‑voting standard in uncontested elections, and quorum requires at least 33⅓% of voting shares present or represented by proxy.
As of the record date, 96,642,822 common shares were outstanding, and non‑voting pre‑funded warrants were exercisable into up to 2,931,293 additional common shares. Two major holders, FMR LLC and Avoro Capital Advisors LLC, beneficially own 9.13% and 5.86% of the common shares, respectively, while all current directors and executive officers together beneficially own 2.91%.
Xenon Pharmaceuticals Inc. amended and restated its 2025 Inducement Equity Incentive Plan to expand the share pool used for new-hire equity awards. The maximum number of common shares reserved under the plan increased from 900,000 to 1,175,000 shares, subject to adjustment under the plan’s terms.
These shares may be granted as nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, or performance awards, and are intended as inducements for individuals being hired or rehired as employees of Xenon or its subsidiaries. In line with Nasdaq Listing Rule 5635(c)(4), shareholder approval was not obtained for this inducement-only plan.
Xenon Pharmaceuticals Inc. Chief Medical Officer Christopher John Kenney reported routine equity compensation activity and a small open-market sale. On March 12, 2026, he exercised 3,750 Restricted Share Units at $0.00 per share, converting them into 3,750 Common Shares that had vested from a grant made on March 12, 2025.
The RSU award vests in four equal annual installments starting on March 12, 2026, and after this vesting he held 11,250 Restricted Share Units directly. On March 13, 2026, he sold 1,410 Common Shares at an average price of $55.225 per share under a Rule 10b5-1 durable sell-to-cover instruction adopted on December 3, 2025, solely to satisfy tax withholding obligations related to the RSU vesting. Following these transactions, he directly owned 7,069 Common Shares.
Xenon Pharmaceuticals Inc.’s Chief Legal Officer, Andrea DiFabio, reported routine equity compensation activity. On March 12, 2026, 3,750 restricted share units granted on March 12, 2025 vested and were converted into an equal number of common shares at no cost. On March 13, 2026, 1,342 common shares were sold at $55.225 per share pursuant to a pre-arranged Rule 10b5-1 “sell-to-cover” instruction used solely to satisfy tax withholding on the RSU vesting. After these transactions, DiFabio holds 7,301 common shares directly and 11,250 RSUs remain outstanding under the award, vesting in equal annual installments over four years beginning March 12, 2026.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported a combination of equity compensation and a small share sale. On March 12, 2026, RSUs covering 12,500 Common Shares vested and were exercised at $0, increasing his direct shareholdings. On March 13, 2026, he executed an open-market sale of 7,308 Common Shares at $55.225 per share under a pre-arranged Rule 10b5-1 “sell-to-cover” instruction adopted on December 3, 2025, solely to satisfy tax withholding tied to the RSU vesting. Following these transactions, Mortimer holds 19,923 Common Shares directly and 14,300 Common Shares indirectly through his spouse, along with 37,500 Restricted Share Units that remain outstanding.
Morgan Stanley Wealth Management Canada Inc. filed a Form 144 notifying the sale of Common Shares tied to a Restricted share unit award vesting dated 03/12/2026 for 3,750 shares. The notice also lists a 03/10/2026 sale of 2,771 shares by Andrea DiFabio and a reported figure 166,559 appearing in the securities block.
XENE Rule 144 notice reporting proposed and recent transactions in Common Shares. The filing lists 3,750 Restricted Share Units vesting on 03/12/2026 and shows 2,607 Common Shares sold by Andrea DiFabio on 03/10/2026.